Tysabri Delays MS Relapse: Data
TheStreet.com - USA
Biogen Idec (BIIB - commentary - Cramer's Take) and Elan (ELN - commentary - Cramer's Take) presented new data this week showing that Tysabri improved the ...
See all stories on this topic

Biogen's Tysabri sustains effect for 3 years-study
Reuters - USA
... company Biogen Idec (BIIB.O: Quote, Profile, Research) said on Friday that data from an extended trial of its multiple sclerosis drug Tysabri showed that the ...

Biogen, Elan Unveil New Tysabri Data and Imclone Shares Up
Financial News USA (press release) - La Puente,CA,USA
... (NYSE:ELN) said Thursday data from a late-stage study of Tysabri showed it was effective in reducing cognitive degeneration in multiple sclerosis patients. ...

---

fingolimod

FTY720 Reduces Multiple Sclerosis Symptoms By 77% - Sustained Over ...
Medical News Today (press release) - UK
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis ...

---

fampridine

Acordia Proves That Biotech Investing is Volatile, Unpredictable ...
Seeking Alpha - New York,NY,USA
... ACOR) absolutely skyrocketed Monday, by more than 280% by day's end, after the company announced that its Multiple Sclerosis drug Fampridine-SR significantly ...

Ahead of the Bell: Acorda Therapeutics
Houston Chronicle - United States
... In a note to clients, she said she expects the new drug, called Fampridine-SR, will need additional testing, which could take a year. ...

Positive Phase 3 Fampridine-SR Study In People With Multiple ...
eMaxHealth.com - Hickory,NC,USA
Acorda Therapeutics, Inc. announced positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis (MS). ...

Hawthorne biotech company's study brings hope to thousands with MS
The Journal News.com - Westchester,NY,USA
Results from a Phase 3 trial of the drug, known as Fampridine-SR, showed that a greater proportion of people had consistently improved walking speed than ...

Piper Jaffray upgrades Acorda Therapeutics (ACOR) to Outperform
StreetInsider.com (subscription) - Birmingham,MI,USA
Acorda has risen significantly this week after announcing positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple ...

---

rituximab Multiple Sclerosis

FDA Approves Two New Indications for Rituxan(R) in Patients With ...
Yahoo! News (press release) - USA
... Priority Review, two additional uses for Rituxan® (Rituximab) for patients ... including systemic lupus erythematosus, lupus nephritis, multiple sclerosis and ANCA ...
See all stories on this topic

---